Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 19, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-17
DOI
10.1186/s10194-018-0918-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
- (2018) James E. Frampton et al. DRUGS
- Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
- (2018) Andrew M. Blumenfeld et al. JOURNAL OF HEADACHE AND PAIN
- A new era in headache treatment
- (2018) Michail Vikelis et al. NEUROLOGICAL SCIENCES
- Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life
- (2017) Cristina Tassorelli et al. Expert Review of Neurotherapeutics
- Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
- (2017) Brendan Davies et al. JOURNAL OF HEADACHE AND PAIN
- Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life
- (2017) Cristina Tassorelli et al. Expert Review of Neurotherapeutics
- OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
- (2017) Chia-Chun Chiang et al. Therapeutic Advances in Neurological Disorders
- Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
- (2017) Simona Guerzoni et al. Frontiers in Neurology
- Chronic migraine treatment: from OnabotulinumtoxinA onwards
- (2016) Andrea Negro et al. Expert Review of Neurotherapeutics
- Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
- (2016) I. Aicua-Rapun et al. JOURNAL OF HEADACHE AND PAIN
- Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
- (2016) Simona Guerzoni et al. JOURNAL OF HEADACHE AND PAIN
- Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
- (2016) Michail Vikelis et al. JOURNAL OF HEADACHE AND PAIN
- Chronic migraine treatment: from OnabotulinumtoxinA onwards
- (2016) Andrea Negro et al. Expert Review of Neurotherapeutics
- A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
- (2015) Andrea Negro et al. JOURNAL OF HEADACHE AND PAIN
- Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine
- (2015) P. Barbanti et al. NEUROLOGICAL SCIENCES
- The diagnosis and treatment of chronic migraine
- (2015) Mark W. Weatherall Therapeutic Advances in Chronic Disease
- Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
- (2014) Eva Cernuda-Morollón et al. CEPHALALGIA
- Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
- (2014) Stephen D Silberstein et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications
- (2011) Ninan T. Mathew HEADACHE
- Prophylaxis of migraine: general principles and patient acceptance
- (2011) Domenico D'Amico et al. Neuropsychiatric Disease and Treatment
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
- (2010) SK Aurora et al. CEPHALALGIA
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
- (2010) HC Diener et al. CEPHALALGIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now